DS 3032b

Drug Profile

DS 3032b

Alternative Names: DS-3032; DS3032b

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Daiichi Sankyo Inc; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Leukaemia; Lymphoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 15 Sep 2017 MD Anderson Cancer Center and Daiichi Sankyo agree to co-develop DS-3032b for Acute myeloid leukemia
  • 05 Dec 2016 Interim efficacy and adverse event data from a phase I trial in Multiple myeloma (Second-line therapy or greater) presented at the 58th Annual Meeting of the American Society of Haematology (ASH-2016)
  • 05 Dec 2016 Daiichi Sankyo plans combination studies for Acute myeloid leukemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top